Below are all the posts — topics as well as replies — that mention the hashtag #biotech.
Mention #biotech in your post to continue the discussion!
Novo Nordisk, the Danish dr-g manufacturer behind the weight-loss and diabetes dr-g Ozempic and other medications, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech company with a dr-g in a late-stage trial to treat a fatal liver disease.
https://www.morningstar.com/news/marketwatch/20251009145/novo-nordisk-is-paying-up-to-52-billion-for-a-san-francisco-biotech-working-on-liver-disease
The Massachusetts biotech sector is facing its steepest round of job cuts in more than a year, with 27 companies eliminating a combined 1,800 jobs during the third quarter of 2025, according to the Boston Business Journal. This marks the highest quarterly loss of biotech positions since the second quarter of 2024, underscoring ongoing financial and market pressures within the industry.
The layoffs span a wide range of organizations, from major pharmaceutical employers to smaller research-driven startups. Companies that reduced staff include IO Biotech, KALA Bio, Sutro Biopharma, Biogen, Heidelberg Pharma, Rome Therapeutics, Seres Therapeutics, Arvinas, Novo Nordisk, Bristol Myers Squibb, Arsenal Biosciences, X4 Pharmaceuticals, and Innate Pharma. Collectively, the cuts affected roles across dr-g development, research, operations, and administrative functions.
Industry analysts point to a combination of factors driving the reductions: slowing deal activity, tighter funding conditions for emerging companies, and strategic pipeline shifts among larger pharmaceutical players. Some firms cited the need to focus resources on late-stage programs or more commercially promising therapies, while others faced direct setbacks such as failed trials or lost partnerships.
Despite the downturn, Massachusetts remains one of the nation’s most active biotech hubs, with billions of dollars in venture investment and ongoing expansion projects. However, the rising tally of layoffs has raised concerns about the sustainability of growth in the sector. Industry observers note that while some displaced workers may find opportunities in better-funded or expanding biotech firms, the wave of cuts highlights an increasingly challenging environment for both startups and established players.
Exelixis
https://www.sfgate.com/tech/article/bay-area-biotech-company-worth-10-billion-layoff-21020576.php
Massachusetts Biotech Sector Faces Slowdown in Venture Funding and Increased Layoffs
A new report from the Massachusetts Biotechnology Council (MassBio) has outlined concerning trends within the state's biotech sector.
https://www.geneonline.com/massachusetts-biotech-sector-faces-slowdown-in-venture-funding-and-increased-layoffs/
GeneOnline
Aug/26/2025 09:24 PM
Location: Massachusetts
Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell Labs model to biotech.
https://www.fiercebiotech.com/biotech/arena-bioworks-19-months-after-splashy-launch-lays-30-its-staff
Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell Labs model to biotech.
Changes at Arena BioWorks follow events that have shaken confidence in gene therapies.
https://www.fiercebiotech.com/biotech/arena-bioworks-19-months-after-splashy-launch-lays-30-its-staff
gilead sciences (tmunity therapeutics) – philadelphia, pennsylvania – biotech cell therapy division – shut down center city office – last 14 positions eliminated by end of june 2025 – part of office consolidation under kite pharma – former east norriton manufacturing facility now operated by resilience
https://www.nbcboston.com/boston-business-journal/mass-cancer-biotech-cuts-25-of-its-workforce/3787827/